Federated Hermes’s Enliven Therapeutics ELVN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$12.4K Buy
+271
New +$14.8K ﹤0.01% 1803
2025
Q4
– Sell
-10,811
Closed -$221K – 2098
2025
Q3
$221K Sell
10,811
-5,287
-33% -$107K ﹤0.01% 1491
2025
Q2
$323K Sell
16,098
-52,953
-77% -$1M ﹤0.01% 1426
2025
Q1
$1.36M Sell
69,051
-48,501
-41% -$1.04M ﹤0.01% 1031
2024
Q4
$2.64M Buy
+117,552
New +$3.05M 0.01% 871
2023
Q2
– Sell
-243
Closed -$5.32K – 2136
2023
Q1
$5.32K Sell
243
-17
-7% -$346 ﹤0.01% 1928
2022
Q4
$4.25K Sell
260
-134
-34% -$2.14K ﹤0.01% 1942
2022
Q3
$4K Sell
394
-542
-58% -$3.2K ﹤0.01% 1907
2022
Q2
$5K Sell
936
-24
-3% -$117 ﹤0.01% 1895
2022
Q1
$7K Buy
960
+266
+38% +$1.75K ﹤0.01% 1916
2021
Q4
$6K Buy
694
+275
+66% +$3.61K ﹤0.01% 1976
2021
Q3
$7K Buy
+419
New +$8.71K ﹤0.01% 2017

Other funds holding ELVN

Federated Hermes's ELVN Position: Q3 2026 in Review

Federated Hermes opened a new position in Enliven Therapeutics (ELVN) in Q3 2026: 271 shares worth $12.4K. The stake represents ﹤0.01% of the portfolio and ranks #1803 among its holdings. This is a return to the name: Federated Hermes previously reported a position in ELVN as recently as Q3 2025.

Federated Hermes first reported a position in ELVN in Q3 2021 and has held it in 12 quarters since. The position peaked at $2.64M in Q4 2024. 216 funds tracked by Wall St. Rank hold ELVN as of Q3 2026.

  • Federated Hermes held 271 shares of Enliven Therapeutics worth $12.4K as of Q3 2026.
  • Enliven Therapeutics was a new Federated Hermes position in Q3 2026.
  • Enliven Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q3 2026, its #1803 holding.
  • Federated Hermes first reported a position in Enliven Therapeutics in Q3 2021 and has held it in 12 quarters since.
  • Federated Hermes's Enliven Therapeutics position peaked at $2.64M in Q4 2024.
  • 216 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2026.

Based on Federated Hermes's 13F filing for Q3 2026, filed 12 Nov 2026.